Lubiprostone Shortage: What Providers and Prescribers Need to Know in 2026

Patients taking Lubiprostone (Amitiza) for chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), or opioid-induced constipation (OIC) are increasingly reporting difficulty filling their prescriptions in 2026. This provider-focused article covers the current supply landscape, clinical prescribing considerations during periods of limited availability, and practical tools your team can use to help patients access their medication.

Current Availability Status (2026)

As of early 2026, Lubiprostone is not listed on the FDA Drug Shortage database. There is no declared national shortage. However, the practical reality for many patients is significantly different from this regulatory status. The following factors are contributing to inconsistent real-world availability:

• Patent expiration (2024–2025): Amitiza's patents expired, allowing generic entry. The generic supply chain is still maturing, with limited manufacturers in production.
• Limited generic manufacturers: Currently, only a few manufacturers produce generic Lubiprostone, making the supply vulnerable to any production disruption.
• Pharmacy stocking decisions: Chain pharmacies stock based on local demand. Locations with low Lubiprostone prescription volumes may not routinely carry it.
• Formulary and prior authorization complexity: Most commercial and Medicaid plans require prior authorization. Step therapy requirements (typically documented failure of polyethylene glycol or other agents) can delay access even when the drug is in stock.

Prescribing Considerations During Availability Challenges

Brand vs. Generic Substitution

Generic Lubiprostone is therapeutically equivalent to brand Amitiza. Unless there is a specific clinical reason to maintain brand therapy, prescribing generically or allowing generic substitution will improve your patient's ability to fill their prescription and substantially reduce out-of-pocket costs ($60–$150 for generic vs. $400–$530 for brand for a 30-day supply). Verify your patient's insurance formulary, as many plans now preferentially cover the generic.

Prior Authorization: Documentation That Helps

For most commercial and Medicaid plans, prior authorization for Lubiprostone requires documentation of:

• Adequate trial and failure or intolerance of at least one OTC osmotic laxative (e.g., polyethylene glycol) for CIC/IBS-C
• For IBS-C: confirmation of female sex (≥18 years) as Lubiprostone's IBS-C indication is sex-restricted
• For OIC: confirmation of chronic, non-cancer pain and adequate documentation of current opioid regimen

Proactively documenting these elements in your patient's chart before submitting the PA can significantly reduce turnaround time and resubmission burden on your staff.

Hepatic Impairment: Required Dose Adjustments

Lubiprostone requires dose adjustment for hepatic impairment (CIC indication). When considering alternatives for patients with liver disease, note that some alternatives (like linaclotide) are minimally absorbed and may not require similar adjustments. Current Lubiprostone dosing for hepatic impairment:

• Moderate hepatic impairment (Child-Pugh Class B): 16 mcg twice daily
• Severe hepatic impairment (Child-Pugh Class C): 8 mcg twice daily; may escalate to full dosing if tolerated and adequate response not achieved

Drug Interaction Alert: Methadone

For patients on methadone (a diphenylheptane opioid), note that non-clinical studies show methadone dose-dependently reduces ClC-2 activation by Lubiprostone. The FDA label states that effectiveness for OIC has not been established in patients taking methadone. In these patients, PAMORA therapy (naloxegol, naldemedine) is the more appropriate first-line OIC treatment.

Clinical Alternatives When Lubiprostone Is Unavailable

When Lubiprostone cannot be sourced, the following evidence-based alternatives are appropriate based on indication:

For CIC:

• Linaclotide (Linzess) 145 mcg once daily (CIC) — GC-C agonist; increases intestinal fluid secretion; once-daily dosing on empty stomach
• Plecanatide (Trulance) 3 mg once daily — GC-C agonist; pH independent; can be taken with or without food; favorable tolerability profile
• Prucalopride (Motegrity) 2 mg once daily — 5-HT4 agonist; promotes pan-colonic motility; useful when secretagogues are ineffective

For IBS-C (women ≥18):

• Linaclotide (Linzess) 290 mcg once daily (IBS-C) — also addresses abdominal pain component, which lubiprostone addresses less effectively
• Plecanatide (Trulance) 3 mg once daily — ACG guidelines support as equivalent option to linaclotide for IBS-C
• Tenapanor (Ibsrela) 50 mg twice daily — NHE3 inhibitor; addresses both bowel frequency and abdominal pain in IBS-C

For OIC:

• Naloxegol (Movantik) 25 mg once daily — PAMORA; oral; addresses peripheral opioid receptor blockade directly
• Naldemedine (Symproic) 0.2 mg once daily — PAMORA; once-daily oral; newer agent with favorable GI tolerability data

How to Help Your Patients Find Lubiprostone

Refer patients to medfinder for providers — a service that calls pharmacies near the patient to find which ones have Lubiprostone in stock. For more clinical guidance on supporting patients through drug access challenges, see our provider guide to helping patients find Lubiprostone.